Schedule 13G ownership disclosure

Fennec Pharmaceuticals Inc

Common Shares, no par value · CUSIP: 31447P100

Event date: 2025-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Southpoint Master Fund, LP

    Shares: 2,744,741 · Class: 8.0%

  • Southpoint Capital Advisors LP

    Shares: 2,744,741 · Class: 8.0%

  • Southpoint Capital Advisors LLC

    Shares: 2,744,741 · Class: 8.0%

  • Southpoint GP, LP

    Shares: 2,744,741 · Class: 8.0%

  • Southpoint GP, LLC

    Shares: 2,744,741 · Class: 8.0%

  • John S. Clark II

    Shares: 2,744,741 · Class: 8.0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001012975-26-000043
Form type
SCHEDULE 13G/A
Filer
FENNEC PHARMACEUTICALS INC.
CIK
CIK 1211583
Filed
Jan 14, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub